michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. 3.77% last quarter and 3.47% this quarter. And again, that is -- as Matt said, that's without the consumer side. That's just commercial. And it also does not have the loan fees that you'd see that hit the ledger.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Look, I think the risk capture is always one of the factors that you have to deal with when you're in an SEP environment. I think we've got some experiences we talked about, the numbers that we're seeing come in look a lot like what we saw as part of the OE process. So we've tried to give reasonable accommodation for that in the MLR guidance that we've provided.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you, George. So question about the EBITDA. Yes, there are really a couple of different things, Bjorn here. One, and you heard me earlier in the Q&A actually talked a little bit about the expectation that our peer margin is going to moderate in the second half in parts driven by sort of the additional investments into our expansion and office footprint, etcetera. The other thing that I would just mention here is, that will really continue to invest in our growth on the G&A line and also on the sales and marketing line, whether that is continuing to build our technology our brand presence, whether that is continuing to build our service offering for the members working at our health network partners, enterprise customers providers. So yes, we really want to make sure that we continue to grow in a responsible way. And it also means that we continue to invest in our operations. So that's a little bit of what you're going to see in the second half. And Amir if you want to talk a little bit about the other question.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Clearly, if it's -- if there is a pause if you will, and it's the same blade, the challenges are associates. Obviously, we want to provide them with an opportunity, to find other work if there is uncertainty, with whether it goes forward, but, and that's what we're going to do. But as far as the ramp-up, if it's the existing line, it's really about being able to hire for the existing lines. It's really being about -- being able to hire associates to ramp it. So, if you think about having to hire a workforce if -- again, if there is a pause and our existing workforce finds other work, then it's probably a six-month process to do that.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. You know, this is Sandeep, Brian. You know, Prism is so exciting. I think it's so exciting because, you know, this whole open architecture allows us to go after a market which we would have -- which would have taken longer for us to board and address, right? So, we have three clients on it which are significant.
We have a pipeline which just continues to grow there but our ability to position this in multiple industries is really interesting. You know, when we talked to you earlier, we talked about this being a big mover in the asset management world. But really, what we're also finding is it has a lot of receptivity in the insurance sector. And the reason for that is the larger insurers have other accounting engines and they can't replace all of them at the same time.
And so, that conversation, being able to have those conversations now, I think, is very, very helpful. So, they don't always count as just Prism deals as much as how do you bring the pipeline forward and build a pipeline you have had trouble building otherwise.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
We do believe there is that opportunity, because we're able to supply that -- when I talk about conversions at distributors or conversions at contractors, that is one of those factors that allow -- because we can respond.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, good afternoon. With respect to some of the changes in rebating strategies, can you just maybe provide an indication of whether or not those were universally applied to existing user base versus new accounts? And the reason I asked the question, I guess, just looks like, purchases by new accounts were a little bit stronger perhaps than they have been in the past couple of quarters. And then, follow-up question for Melissa. Given the fact that the full -- the salesforce hasn't really been able to be fully engaged I guess in a traditional sense, since the pandemic began, what should we be thinking about in terms of changes to the overall marketing plan, messaging, strategy, beginning second-half of this year when we're all sort of assuming something resembling closer to pre-pandemic conditions? Thanks.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. Thanks, Jade.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. It's -- we had a piece of it. We wanted to buy the -- buy out the whole entirety because we have business plan to focus on building out platforms for the local small and medium-sized businesses, being able to compete in -- with the larger agencies out there and acquiring CTV inventory, OTT inventory, and we've had significant success utilizing the platform. And by taking internally, we think we can have a growth into a major SaaS business as well.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. What I would say is if you look at esoteric testing, which includes oncology, that actually went down less than the other testing that we did, more routine testing at the beginning of the pandemic. But as we stand here today, they both come back and it looks about what you would expect. It's about a 60% to 40% breakout of our business, 60% on a more standard testing and revenue and about 40% on the esoteric including oncology. So we see them both coming back.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. No, I get the question and ...

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Roger, and thanks for asking the CV questions.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you, Rodrigo. Yes that's the idea. I anticipate that this strategy in the first quarter. If you remember Enel Americas anticipated dividends in the frequency as and know that's why Enel Americas has a batch today. Because, of course, we are in a growth phase in the Kansas. So now that we are seeing that the countries, especially in this case Brazil in Colombia as mentioned, so we can invert this trend. So what we'll do is to have let's say a deal even pay in higher than the dividend payout right in a progressive way. So that's the idea. The idea is to reduce as a little by little these debts in Enel Americas because with the debt is more efficient, if it stays in the country.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hey, Jade. It's Matt. Thank you for joining us. I appreciate the question. I'd say, right now, we're primarily focused on managing the originations through repayments. Obviously, I think as we look at the stock price and you mentioned where we are versus book value with and without CECL, we'll continue to track that and think about raising capital, if we can do so, accretively. Certainly, the pipeline is very big. Right now, it feels like there's been some pent-up demand over the course of the last six to nine months. And so, we're seeing good opportunities there. I think from the debt side, we're going to take advantage of some of the things you mentioned. The markets are very strong right now on the liability side of the equation certainly. The CLO market has been very active and is pricing at very attractive levels. But I think from a total debt perspective, we're in a good place. So, we don't expect to add debt. But, obviously, we can change forms of debt or refinance existing facility to take advantage of some of the current environment. So, right now, I think we're again most focused on repayments and potential equity to the extent we can do so accretively.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hey, thanks. Just want to line up a couple of numbers. I think you said that streaming revenues grew 97% in Q4, you also indicated that the run rate at the end of the quarter went from $125 million last year to $300 million this year, which is obviously a lot more than 100% growth rate. Is it -- is the delta there just a reflection of you having a lot of ads in December? Thanks.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Okay. Industrial and chemical, we have two main business in the industrial, chemical, The first one is the Solarsoft business, as I mentioned you before is like 100,000 metric tons expected for this year and the second one is that the traditional use of industrial chemical and this is close to 65,000 metric tons per year and we expect to have this year between 65,000 metric tons to 70,000 metric tons of what we call the traditional industrial chemical.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Adam, our expectation is to grow the combined business. And we know through every acquisition prior and we expect through this acquisition when we service your customer and your vendor partners well, you get more business, not less. And that's what our expectation for this transaction.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, I'll take that, Brad. In terms of sort of -- we thought about the guide, a couple of things. I think, first, keep in mind, this Q4, we anticipate there would be a bit of a slowdown from a services standpoint. I kind of called that out in my prepared remarks.
We do anticipate seeing a little bit of that -- a little bit of slowness coming in from that perspective. So I think, that's one thing. Do keep in mind, a year-ago same quarter, we did have a $2 million positive impact from a volume play from one of our customers where we got to catch that revenue up. So that is in there when you kind of do a quarter -- Q4-to-Q4 comparison that piece is in there as well.
So I want to make sure I point that out. We did not anticipate a similar thing in this quarter. So maybe two big things I would point out. But I don't know if there's anything else you kind of big picture driving anything other than the things you've mentioned.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Thanks for taking my questions and congratulations on getting that commercial agreement with T-Mobile. I know the team has worked exceptionally hard on that for a long time now. You mentioned that the agreement was in line with what you kind of had expected.
Is that to assume at a high level that this is kind of similar to the Sprint model where it's like a monthly ARPU that you guys receive or some revenue share with T-Mobile without diving too much into specifics.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I believe so, Gautam. And what we are going to and you've seen in the numbers today is that the backlog situation across the business is at $1.1 billion. And that's what -- that's the impetus to drive the organic growth despite what happens in the residential AC cycle. And that will support the organic growth in the business for '22.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. I'm just going to give you some background, and I'm going to let Nick talk to it as well. We've had the WW Health Solutions business for year. I came in and realized this is not the business that is really going to take us into the future. So the first number of years, which you didn't hear me talk about it very much, was completely rebuilding that business. The platform, the technology, that's why we opened the tech hub in Toronto as well as the team as well as what our offering was across employers, payers, physicians, etc.
And so the platform now that we have is what we can really move forward with. So as I mentioned, we're now with the CVSs and the Welltoks and other areas, and that is going to build based on the timing of when they sell in over the course of the year. So we have fairly good visibility to be confident to say that we're going to see growth in that business over the course of 2021, that can then scale that much more significantly in 2022 based on the timing.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
No. That's actually one of the, I would say, trends that has given us that probably increased confidence to continue to grow. We're really seeing this across the board. We're seeing this in new geographies and old geographies.
We're seeing this in older centers, older care teams, newer centers. And actually, the reason why that gives us comfort is we don't think this is some problem of the quality is going down as we scale or we're not actually finding the same success in new markets, etc. I think it's just -- we really gave it the external factors that we need to manage through versus some difference in Oak Street performance as we grow.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I'm not trying to really say anything about '22 with the exception that it looks like it continues to be strong, is the qualitative statement I made. It's too soon for us to put numbers around '22, Stacy. And when we look at WFE, so a quarter ago, we were talking about trending above 75. Tim now said we see it trending above 80. I think overall, it's a second half weighted WFE profile. DRAM looks solid in the second half. Foundry/logic looks pretty good in the second half, too. I think NAND probably, as I sit here today, is more balanced half-on-half. And a quarter ago, we said looked like it was a little bit second half. I can still see that potentially happening, but there's some customer investment timings that might occur more in the first half of next year. Right now, it looks kind of balanced half-on-half as we sit here today.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you, Sandip.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great. Thanks, everyone for joining us this morning. As usual, we are available for questions and follow-ups. So, have a great day.
Thank you.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So AlloCell is specific to allogeneic cell therapy, therapeutic. So there we're looking at, you're right, the pharma kinetic which includes what you described as we look at different C max, we look at the persistence. And so -- but it's not part of multi-modality. So it's not the thing which we've been doing, for example, with kidney care, heart care, and lung care, for example. So it's there in solid organ where we had multi-modality and this is an allogeneic cell therapy. We're really just measuring to sell concentrations and then seeing if there is any clinical interventions and decisions that need to be make as we work with the partners on this.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Frank.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hey, guys. Thanks for taking the questions. I'll ask my two upfront, too, if I could. I guess first one would be, Bill, you know, investors have been waiting a long time to kind of see how the big data center companies evolve their edge strategies.
You've already struck a partnership a week or two ago, and it sounds like you're planning on doing some more. I was wondering if you could kind of elaborate a little bit now on what you're looking for and how you settled on this path that you've chosen with Atlas to begin with. And then maybe, Andy, just -- I want to kind of go back to the power thing. You know, 90% pass-through, that leaves about 20 million on the income statement, a few pennies.
You know, it's still about $15 million of exposure. Is that kind of what you're budgeting to potentially happen in 2022? Thanks.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Did you say Sorry, Joe.

    Prediction (one of UP, DOWN, SAME): SAME